It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.

①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.

cls.cnOct 18 01:13 ET

Star Evening News | Minmetals New Energy, Bio-Thera Solutions, and 6 other companies announced their shareholding reduction plans. Vertical and horizontal shares receive an administrative supervision decision letter from Sichuan Securities Regulatory Bure

1. Guangdong may introduce demonstration clauses for technology insurance such as biomedical and integrated circuits; 2. Shenzhen: Accelerating the establishment of a multi-billion-dollar Shenzhen semiconductor and integrated circuit industry investment fund; 3. The Shanghai Stock Exchange terminates the listing and issuance review of Feixiang Technology on the Star Market.

cls.cnOct 14 09:02 ET

Controlling shareholder's high pledge rate is questioned, Tonghua Dongbao: revenue will recover quarterly in the second half of the year | Directly hit the earnings conference

① The high pledge rate of shares held by Tonghua Dongbao's controlling shareholder was questioned. Li Jiahong, chairman of the company, said that it was due to the long investment project cycle of Dongbao Group; ② In terms of performance, Li Jiahong expects the company's revenue to recover quarterly in the second half of the year; ③ the company also explained the sales situation of new products.

cls.cnOct 10 05:26 ET

Star Evening News | Xi'an Bright Laser Technologies plans to invest 1 billion yuan to build a material production line. Jiangsu Aidea Pharmaceutical has completed the acquisition of 31.161% equity of Nanda Pharmaceuticals.

1. Guangdong Jiayuan Technology signed the "Investment Intention Termination Agreement" with the Meixian District People's Government of Meizhou City; 2. Xi'an Bright Laser Technologies, opt machine vision tech co., ltd., NAIKE Equipment disclosed the repurchase plan; 3. Shanghai Allist Pharmaceuticals Co., Ltd.: AST2303 slice obtained the drug clinical trial approval notice.

cls.cnSep 23 09:04 ET

Significant layoffs? Remegen responds: It is a normal business optimization. The recently adapted indication for Taitsip will be applied for listing.

①Regarding the online rumors of layoffs, the secretary of the board of directors of Remegen stated that the company has been sorting out its business since last year, and the optimization of positions and personnel is based on work needs, without a rigid proportion; ②The other party revealed that the severe myasthenia gravis indication of the targeted drug Taituxip is expected to apply for market approval soon. However, Taituxip is facing multiple competitions in the market.

cls.cnSep 20 04:13 ET

Jiangsu Sihuan Bioengineering's actual controller has been given a "red card" for lifetime market ban again, and Lu Keping and his son are expected to be fined nearly 30 million yuan. Read the announcement quickly.

①Due to the ST Weichuang suspected of illegal disclosure of information, jiangsu sihuan bioengineering's ultimate controller Lu Keping and the company's director Lu Yu father and son received a "sky-high" fine. ②In this case, Lu Keping has issues such as keeping the identity of the ultimate controller "secret" and has once again been subjected to a lifetime ban from the securities market. ③According to the pre-notification of administrative penalties, Lu Keping and his son were fined a total of nearly 30 million yuan.

cls.cnSep 18 19:13 ET